We therefore built in vitro models, from which three distinct cancer cell gene expression signatures specific for luminal, HER2‐positive, and basal tumors were derived and subsequently challenged as prognostic biomarkers in clinical tumors. The gene discussed is ERBB2; the disease is cancer.